文献速递浆细胞疾病

Myeloma XI:CVD方案对诱导缓解不佳的新诊断多发性骨髓瘤的强化治疗

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2019-10-14

Myeloma XI是一项多中心、开放标签、随机、III期适应性设计试验,评估对免疫调节剂诱导治疗后仅达部分缓解或微小缓解的新诊断多发性骨髓瘤患者,采用CVD方案(环磷酰胺+硼替佐米+地塞米松)强化治疗对比无强化治疗的疗效。共583例患者随机分配至CVD组(289例)或无治疗组(294例)。

要点

  • 对诱导治疗后仅达部分缓解或微小缓解的新诊断多发性骨髓瘤患者,CVD强化治疗显著延长无进展生存期
  • CVD强化治疗未显著改善总生存期
  • CVD方案最常见3/4级不良事件为血液学毒性,包括中性粒细胞减少、血小板减少和贫血

核心结论

  • 对于免疫调节剂诱导治疗后缓解不佳的新诊断多发性骨髓瘤患者,CVD强化治疗较无强化治疗显著改善无进展生存期,但未改善总生存期。

研究设计与样本

  • Myeloma XI为多中心、开放标签、随机、III期适应性设计试验,在英国110家NHS医院开展。
  • 共纳入583例已完成诱导治疗(环磷酰胺+沙利度胺+地塞米松或环磷酰胺+来那度胺+地塞米松)且仅达部分缓解或微小缓解的新诊断多发性骨髓瘤患者,按1:1随机分配至CVD组(289例)或无治疗组(294例)。

主要发现

  • CVD组最常见3/4级不良事件为血液学毒性:中性粒细胞减少18例(7%)、血小板减少19例(7%)、贫血8例(3%);CVD组无治疗相关死亡。

临床怎么用

  • 对免疫调节剂诱导治疗后仅达部分缓解或微小缓解的新诊断多发性骨髓瘤患者,可考虑CVD强化治疗以延长无进展生存期。
  • CVD强化治疗未显示总生存获益,且需关注血液学毒性。

局限性

  • 诱导治疗后仅48%(583/1217)达到部分缓解或微小缓解的患者进入强化随机分组,大量患者未进入该随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents could be given in combination or in sequence on the basis of previous response. We aimed to assess the clinical value of maximising responses by using therapeutic agents with different modes of action, the use of which is directed by the response to the initial combination therapy. We aimed to assess response-adapted intensification treatment with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment in patients with newly diagnosed multiple myeloma who had a suboptimal response to initial immunomodulatory triplet treatment which was standard of care in the UK at the time of trial design. METHODS: The Myeloma XI trial was an open-label, randomised, phase 3, adaptive design trial done at 110 National Health Service hospitals in the UK. There were three potential randomisations in the study: induction treatment, intensification treatment, and maintenance treatment. Here, we report the results of the randomisation to intensification treatment. Eligible patients were aged 18 years or older and had symptomatic or non-secretory, newly diagnosed multiple myeloma, had completed their assigned induction therapy as per protocol (cyclophosphamide, thalidomide, and dexamethasone or cyclophosphamide, lenalidomide, and dexamethasone) and achieved a partial or minimal response. For the intensification treatment, patients were randomly assigned (1:1) to cyclophosphamide (500 mg daily orally on days 1, 8, and 15), bortezomib (1·3 mg/m2 subcutaneously or intravenously on days 1, 4, 8, and 11), and dexamethasone (20 mg daily orally on days 1, 2, 4, 5, 8, 9, 11, and 12) up to a maximum of eight cycles of 21 days or no treatment. Patients were stratified by allocated induction treatment, response to induction treatment, and centre. The co-primary endpoints were progression-free survival and overall survival, assessed from intensification randomisation to data cutoff, analysed by intention to treat. Safety analysis was per protocol. This study is registered with the ISRCTN registry, number ISRCTN49407852, and clinicaltrialsregister.eu, number 2009-010956-93, and has completed recruitment. FINDINGS: Between Nov 15, 2010, and July 28, 2016, 583 patients were enrolled to the intensification randomisation, representing 48% of the 1217 patients who achieved partial or minimal response after initial induction therapy. 289 patients were assigned to CVD treatment and 294 patients to no treatment. After a median follow-up of 29·7 months (IQR 17·0-43·5), median progression-free survival was 30 months (95% CI 25-36) with CVD and 20 months (15-28) with no CVD (hazard ratio [HR] 0·60, 95% CI 0·48-0·75, p<0·0001), and 3-year overall survival was 77·3% (95% Cl 71·0-83·5) in the CVD group and 78·5% (72·3-84·6) in the no CVD group (HR 0·98, 95% CI 0·67-1·43, p=0·93). The most common grade 3 or 4 adverse events for patients taking CVD were haematological, including neutropenia (18 [7%] patients), thrombocytopenia (19 [7%] patients), and anaemia (8 [3%] patients). No deaths in the CVD group were deemed treatment related. INTERPRETATION: Intensification treatment with CVD significantly improved progression-free survival in patients with newly diagnosed multiple myeloma and a suboptimal response to immunomodulatory induction therapy compared with no intensification treatment, but did not improve overall survival. The manageable safety profile of this combination and the encouraging results support further investigation of response-adapted approaches in this setting. The substantial number of patients not entering this trial randomisation following induction therapy, however, might support the use of combination therapies upfront to maximise response and improve outcomes as is now the standard of care in the UK. FUNDING: Cancer Research UK, Celgene, Amgen, Merck, Myeloma UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Jackson GH, Davies FE, Pawlyn C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019. PMID: 31624047. doi:10.1016/S2352-3026(19)30167-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。